Frontline therapy in multiple myeloma therapy: current evidence and future research
Professor Graham Jackson (Newcastle, UK) held a ‘meet the expert’ session at BSH 2019 covering the rapidly changing world of frontline therapy in myeloma.
Professor Graham Jackson (Newcastle, UK) held a ‘meet the expert’ session at BSH 2019 covering the rapidly changing world of frontline therapy in myeloma.
The 2019 annual meeting of the BSH showcased the best UK research with over 36 sessions covering a range of important issues related to the treatment of haematological… read more.
Faouzi Djebbari (Oxford) also gives his thoughts on the unmet needs of the newly diagnosed MM patient who is ineligble for stem cell transplantation.
Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.
Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.
Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.
Among the late-breaking clinical trial abstracts at UEG Week were new data for ustekinumab in UC, a new formulation for subcutaneous administration of vedolizumab, and early clinical data… read more.
Professor Stefan Schreiber (Germany) discusses the future of therapies in IBD.
Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.
Dr Johan Burisch (Denmark) reviews data he presented on the cost saving effect of biological therapy in patients with IBD.
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.